NEW YORK, March 29, 2018 -- According to a new research report titled “Constipation Therapeutics Pipeline Analysis 2017” published by P&S Market Research, Constipation therapeutics pipeline currently exhibits strong prospects with approximately 18 drug candidates.
Request for Sample Copy of this Research Report: https://www.psmarketresearch.com/market-analysis/constipation-therapeutics-pipeline-analysis/report-sample
The study analyzed that the constipation therapeutics pipeline comprises approximately 18 drug candidates in different stages of development. Most of the drugs in pipeline for the treatment of constipation are in late stage of development. Constipation is a common functional gastrointestinal (GI) disorder that is most prevalent in the elderly and female population. According to the journal Clinical Interventions in Aging, published in 2015, the prevalence of the disease is around 20% in the world population, varying between 2% and 27% in different countries. The economic impact of chronic constipation is significant in the U.S., with around 100,000 constipation-related hospitalizations annually.
There has been considerable increase in the prevalence of GI disorders, such as non-alcoholic fatty liver disease, diabetes, pancreatitis, and acidity, in people. These problems have a huge impact on the digestion process, which, in turn, causes constipation. It has also been observed that synthetic foods too cause indigestion in people, which results in constipation. Thus, unhealthy dietary behavior too increases the chances of occurrence of constipation. Thus, increasing prevalence of GI disorders contributes as one of the key drivers for the development of drugs to treat constipation.
Browse Full Report with detailed TOC on “Constipation Therapeutics Pipeline Analysis” at: https://www.psmarketresearch.com/market-analysis/constipation-therapeutics-pipeline-analysis
With advances in technology, many pharmaceutical companies are leveraging new and improved technologies for the development of drug candidates to treat constipation. These technologies are helpful in the development of drugs as either combination therapies or single-agent therapies. They also allow development of specific targeted therapies with better drug delivery. For instance, Ardelyx Inc. has developed a unique platform that enables to discover targets in the GI tract, which control health and disease processes to optimize drug candidates and to understand their mechanisms of action.
Some of the players involved in the development of drug candidates for the treatment of constipation are Nordic Life Science Pipeline Inc., Enterin Inc., and Yuhan Corporation Ltd.
More Reports Published by P&S Market Research
Alzheimer’s Disease Pipeline Analysis - https://www.psmarketresearch.com/market-analysis/alzheimers-disease-pipeline-analysis
ER+ Breast Cancer Pipeline Analysis - https://www.psmarketresearch.com/market-analysis/estrogen-receptor-positive-breast-cancer-pipeline-analysis
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Contact:
P&S Market Research
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: [email protected]
Web: https://www.psmarketresearch.com
Connect with us: LinkedIn | Twitter | Google + | Facebook


Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal
Apple Restores Telegram to App Store After Content Policy Violation
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation
Telegram Restored on Apple App Store After Temporary Removal
DHL Q2 Profit Jumps 24% as Express Business Drives Growth
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales
Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 



